Skip to main content

LB Pharmaceuticals Inc

LBRX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001691082

No open-market purchases or sales by LB Pharmaceuticals Inc insiders were filed in the last 90 days; 114 institutions reported holding it in 13F filings for Q2 2026, worth $1.00B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by LB Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for LB Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for LB Pharmaceuticals Inc
NameTitleLast reported holdingLast filingFilings, past year
Kroin David10% Owner666,666IndirectAug 3, 20262
Deep Track Capital, LP10% Owner666,666IndirectAug 3, 20262
Deep Track Biotechnology Master Fund, Ltd.10% Owner666,666IndirectAug 3, 20262
Ruffolo Robert RDirector–Jun 5, 20261
Garland J. ScottDirector–Jun 5, 20261
Nussbaum RanDirector1,411,681IndirectJun 5, 20261
Hemrajani RekhaDirector–Jun 5, 20261
Kane William P JrDirector–Jun 5, 20261
Lenz Robert A.Director–Jun 5, 20262
Luse RebeccaDirector–Jun 5, 20261
Deep Track Special Opportunities Fund, LP10% Owner–Feb 10, 20261
Pai Panandiker Kaya KamleshChief Commercial Officer–Dec 11, 20251
Panoff Marc LSenior Vice President, Finance–Sep 29, 20251
Belldegrun Arie10% Owner2,029IndirectSep 16, 20250
Vida Ventures GP III, L.L.C.10% Owner2,029IndirectSep 16, 20250
Vida Ventures III-A, L.P.10% Owner2,029IndirectSep 16, 20250
Vida Ventures III, L.P.10% Owner2,029IndirectSep 16, 20250
Vida Ventures Management Co. LLC10% Owner2,029IndirectSep 16, 20250
Pontifax Management 4 G.P. (2015) Ltd.10% Owner1,411,681IndirectSep 16, 20250
Prensky ZacharyDirector–Sep 12, 20250
Turner Heather DChief Executive Officer–Sep 12, 20250
Soffer GadChief Business Officer–Sep 12, 20250
Eramo AnnaChief Medical Officer–Sep 12, 20250
Silva Richard AnthonySVP, Technical Operations–Sep 12, 20250

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 3, 2026 (view filing)7:28 PM ETJul 304 daysKroin David and 2 others10% OwnerPPurchase+286.2K$34.94+$10.0M–664.6K afterDerivative
Feb 10, 2026 (view filing)4:30 PM ETFeb 64 daysKroin David and 3 others10% OwnerPPurchase+378.4K$21.17+$8.01M–378.4K afterDerivative
Feb 10, 2026 (view filing)4:30 PM ETFeb 64 daysKroin David and 3 others10% OwnerPPurchase+93.9K$21.17+$1.99M–93.9K afterDerivative
Sep 16, 2025 (view filing)6:09 PM ETSep 124 daysKroin David and 2 others10% OwnerPPurchase+2.00M$15.00+$30.0M+291.5%2.69M after
Sep 16, 2025 (view filing)6:09 PM ETSep 124 daysKroin David and 2 others10% OwnerPPurchase+666.7K$15.00+$10.0MNew position666.7K after
Sep 16, 2025 (view filing)3:46 PM ETSep 124 daysBelldegrun Arie and 4 others10% OwnerPPurchase+333.3K$15.00+$5.00MNew position2.03K after2 lots
Sep 16, 2025 (view filing)Sep 124 daysPontifax Management 4 G.P. (2015) Ltd.10% OwnerPPurchase+1.00M$15.00+$15.0M+242.9%1.41M afterDuplicate filing
Sep 16, 2025 (view filing)Sep 124 daysNussbaum RanDirectorPPurchase+1.00M$15.00+$15.0M+242.9%1.41M after